Arca biopharma, inc. (ABIO)
CashFlow / Yearly
Dec'19Dec'18Dec'17Dec'16Dec'15Dec'14Dec'13
Cash flows from operating activities:
Net loss

-5,482

-7,933

-18,490

-16,444

-11,445

-9,689

-6,939

Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation

18

22

27

24

19

12

26

Amortization of right-of-use asset - operating

71

-

-

-

-

-

-

Amortization of other assets

-

-

329

296

189

-

-

Amortization of premiums and discounts on marketable securities

-

-2

-119

-161

-

-

-

Amortization of deferred charges

-

-

-

-

-

67

-

Share-based compensation

151

273

458

576

599

647

283

Change in operating assets and liabilities:
Other current assets

-401

-689

-437

47

-213

-214

-130

Other assets

-

-

-

432

211

545

-

Other assets

-

-

-

-

-

-

-14

Accounts payable

188

-392

-583

841

-431

198

532

Accrued compensation and employee benefits

-21

-607

38

50

340

-130

356

Accrued expenses and other liabilities

-127

-298

193

-3

196

-182

325

Other

-

-

-

-9

-3

2

-

Other

-

-

-

-

-

-

15

Net cash used in operating activities

-

-

-

-14,987

-10,534

-9,406

-5,288

Net cash used in operating activities

-4,801

-8,244

-17,472

-

-

-

-

Cash flows from investing activities:
Purchases of property and equipment

4

4

3

12

11

19

32

Purchases of marketable securities

-

-

5,471

-

-

-

-

Purchases of marketable securities

-

-

-

20,504

-

-

-

Proceeds from maturities of marketable securities

-

3,050

18,400

4,102

-

-

-

Net cash used in investing activities

-4

3,046

12,926

-

-

-

-

Cash flows from financing activities:
Net cash provided by investing activities

-

-

-

-16,414

-11

-19

-32

Proceeds from the issuance of common stock

7,281

3,532

6,551

-

37,000

9,038

1,741

Proceeds from the issuance of preferred stock

-

-

-

-

-

-

20,000

Common stock offering costs

372

117

448

-

2,814

836

-

Repayment of principal on vendor finance agreement

349

311

256

-

193

179

174

Net cash provided by financing activities

-

-

-

-

33,993

8,023

19,156

Net increase (decrease) in cash and cash equivalents

-

-

-

-31,401

23,448

-1,402

-

Net cash provided by financing activities

6,560

3,104

5,847

-

-

-

-

Net (decrease) increase in cash and cash equivalents

1,755

-2,094

-

-

-

-

-

Net increase in cash and cash equivalents

-

-

1,301

-

-

-

13,836

Supplemental cash flow information:
Interest paid

7

8

6

-

-

-

-

Interest paid

-

-

-

-

4

3

3

Income tax refund received

167

54

38

-

-

-

-

Supplemental disclosure of noncash investing and financing transactions:
Common stock offering costs accrued but not yet paid

-

-

7

-11

11

-

-

Leased assets obtained in exchange for operating lease liabilities, upon adoption and extension

93

-

-

-

-

-

-

Change in unrealized loss on marketable securities

-

2

17

-

-

-

-

Change in unrealized loss on marketable securities

-

-

-

-19

-

-

-

Leasehold improvement lease incentive

-

-

-

48

-

-

-